Executive Director Lee Sangmyung of Samsung Biologics: "Focus on Enhancing Networks and Clinical Experience"


Building a 12,200m² Incubator in Songdo


Investing 240 Billion Won in Funds, 25 Billion Won in Grants

Samsung Biologics is set to launch a “three-pronged support system” combining the attraction of Eli Lilly’s “Gateway Lab”—a hub for nurturing biotech startups—in Songdo, Incheon, with investment and support programs. Rather than merely providing infrastructure, the company aims to integrate funding and access to a global network.

Sangmyung Lee, Executive Director at Samsung Biologics, is presenting at 'Bio Korea 2026' held at COEX, Seoul, on the 30th. Samsung Biologics

Sangmyung Lee, Executive Director at Samsung Biologics, is presenting at 'Bio Korea 2026' held at COEX, Seoul, on the 30th. Samsung Biologics

View original image

Isang Myung, Executive Director of Samsung Biologics, unveiled for the first time the operational roadmap for the open innovation center “C-Lab Outside” at “Bio Korea 2026,” held at COEX in Seoul on April 30.


He stated, “Korean biotech companies possess strong fundamental science capabilities and adapt quickly to new technologies, but they comparatively lack the experience of bringing global new drugs to market and accessing global networks.” He added, “Many biotech companies commonly point out the lack of opportunities to showcase their technology and insufficient global connections. Through our collaboration with Eli Lilly, we plan to jointly select and support up to 30 biotech companies capable of developing next-generation therapeutics.”


C-Lab Outside will be located within Samsung Biologics’ Second Bio Campus in Songdo. It will span approximately 12,200 square meters over five floors above ground, equipped with both research and networking spaces.


Executive Director Lee explained, “The research spaces are meticulously designed to guarantee independence, while areas like the rooftop lounge naturally facilitate interaction. The core concept is to realize both independence and connectivity at the same time.”

From Early-Stage to Global Players... Fully Open Across Antibodies, CGT, AI, and More

The center will mainly accommodate early-stage biotech startups. It will open its doors not only to antibody-related companies, but also to those in gene therapy (CGT), chemicals, peptides, and artificial intelligence (AI)-based drug development, encompassing a wide range of technical fields. Detailed admission programs will be released at the end of this year, with formal application, evaluation, and selection procedures scheduled to begin in 2027.


The facility will be jointly operated by Samsung Biologics’ in-house venture incubation program “C-Lab Outside” and Eli Lilly’s Gateway Lab. C-Lab Outside originated at Samsung Electronics and has since expanded to financial affiliates as an external startup incubation model, but this is the first time it is being applied to the bio field.


The funding support system is divided into two main branches. The Life Science Fund, in which major affiliates including Samsung Biologics participate, is worth a total of 240 billion won and is currently being invested. The fund makes investments based on technological competitiveness, regardless of sector—antibodies, RNA, AI, cell and gene therapy (CGT), and more. A leading example is the investment in Korean antibody-drug conjugate (ADC) company AIMEDBIO, which extended beyond equity investment into joint development of ADC payloads and linkers. The company is also considering additional funding internally.


The Industry Promotion Fund is operated independently by Samsung Biologics. Set at 25 billion won over three years starting from the end of this year, it is structured as pure grant funding rather than equity investment. Over half of the fund will be distributed as direct cash support, with the remainder allocated to training and consulting programs as well as support for equipment and infrastructure costs. The primary support targets are companies based in Songdo, with a focus on synergy with Gateway Lab tenants.


Executive Director Lee emphasized, “Since its establishment in 2011, Samsung Biologics has secured over 145 clients, signed more than 165 CDO (contract development organization) contracts, and grown to around 5,800 employees—thanks in large part to the Korean bio ecosystem. Now, it’s time to give back.”





This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing